Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Reddy, Rajender
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites	Completed	3	410	Europe, Canada, US, RoW	Albutein 20% Injectable Solution, Standard medical treatment	Grifols Therapeutics LLC, Instituto Grifols, S.A.	Decompensated Cirrhosis and Ascites	05/24	05/24
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)	Active, not recruiting	3	238	Europe, Canada, Japan, US, RoW	Linerixibat, Placebo	GlaxoSmithKline	Pruritus	10/24	01/25
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	871	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study	Recruiting	3	251	Europe, Canada, Japan, US, RoW	Linerixibat	GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited	Cholestasis	02/27	02/27
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease	Not yet recruiting	2	393	Europe, Canada, Japan, US, RoW	GSK4532990, Placebo	GlaxoSmithKline	Liver Diseases, Alcoholic	12/26	03/27
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)	Recruiting	2	280	Europe, Canada, Japan, US, RoW	Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo	GlaxoSmithKline	Chronic Hepatitis B Virus Infection, Hepatitis B	10/27	10/27
Borges, Kelly
No trials found